Hemodialysis Tops PhilHealth Claims

2026-09-05

Hemodialysis has quietly become the center of PhilHealth’s balance sheet. Coverage for these treatments accounted for the largest share of benefit claims filed with the insurer in the first half of the current reporting period, eclipsing reimbursements for common inpatient admissions and maternity care.

This dominance is not just a billing quirk; it is a clinical warning. Hemodialysis, driven by irreversible loss of nephron function and sustained uremia, sits at the end of the chronic kidney disease pathway, where patients require repeated extracorporeal blood filtration sessions to survive. Each session generates a separate claim, and the aggregate volume now signals how many patients live tethered to dialysis centers, many of them in overstretched public hospitals that depend on PhilHealth reimbursements for operating cash flow.

The financial pattern looks even starker when set against prevention. A system that spends more on hemodialysis than on primary hypertension control or diabetes management is, by design, paying for late-stage complications rather than early intervention. Actuarial pressure follows: frequent high-cost outpatient procedures can strain contribution rates, narrow the fiscal space for other benefits, and force harder choices on benefit design. For patients, the prominence of hemodialysis claims underlines a paradoxical mix of access and fragility, where life-sustaining care is formally covered yet still exposes families to travel costs, income loss, and the constant risk that any delay in reimbursement will ripple through already fragile renal units.

Recommendations